戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  premenopausal (age < 50 years) and 357 were post- menopausal.
2 emale mice and pre- (42.3 +/- 0.5 years) and post-menopausal (61.9 +/- 0.9 years) women.
3 ose-response associations in endometrial and post-menopausal breast cancer, and in degree and duratio
4  with ABS compared with patients with MI and post-menopausal controls (p < 0.05).
5 tly lower in patients with ABS compared with post-menopausal controls (p < 0.05).
6 ncreased in patients with ABS, compared with post-menopausal controls, following acute mental stress
7 ute mental stress in patients with MI versus post-menopausal controls.
8 and PR isoform expression in normal pre- and post-menopausal endometrium, well-differentiated endomet
9 d bone mass through weight-bearing exercise, post-menopausal ERT, and adequate calcium intake.
10 r being hospitalized or diagnosed with ABS), post-menopausal female controls (n = 12), and female pat
11 levels were low in the majority of males and post-menopausal females, but within normal limits for pr
12 's health, such as in oral contraception and post-menopausal hormone therapy.
13 y was a significant risk factor among women; post-menopausal hormones use was only associated with an
14                                            A post-menopausal hot flush consists of profuse physiologi
15 f physiological symptoms that occur during a post-menopausal hot flush.
16 Grandmother Hypothesis to simulate how human post-menopausal longevity could have evolved as ancestra
17 icrobial-dose-doxycycline (SDD) treatment of post-menopausal osteopenic women significantly reduced p
18                                          128 post-menopausal osteopenic women with chronic periodonti
19  above both eroded and formative surfaces in post-menopausal osteoporosis patients, and that this abs
20 sing humanized IL-27 toward the treatment of post-menopausal osteoporosis.
21  remodeling in a widespread disease, such as post-menopausal osteoporosis.
22 s are therapeutic agents in the treatment of post-menopausal osteoporosis.
23 lso improved bone strength in a rat model of post-menopausal osteoporosis.
24 reatment of osteopenic conditions, including post-menopausal osteoporosis.
25 ogen deficiency, replicating many aspects of post-menopausal osteoporosis.
26 usted p-value = 0.015) and more likely to be post-menopausal (p-value = 0.004; BH-adjusted p-value =
27 nificantly shorter survival, specifically in post-menopausal patients with advanced and terminal stag
28        When matched the participants by age, post-menopausal status was still associated with a highe
29                           Increasing age and post-menopausal status were associated with the presence
30 gulates metabolic physiology, highlighted by post-menopausal temperature dysregulation (hot flashes),
31 n independently influenced oral bone loss in post-menopausal women aged <70 years.
32    Between 2001 and 2005, a total of 202 638 post-menopausal women aged 50-74 years were randomly ass
33 th Initiative Hormone Trials enrolled 27,347 post-menopausal women ages 50 to 79 years.
34  cardiomyopathy that occurs predominantly in post-menopausal women and may be triggered by acute ment
35 tion is critical for designing therapies for post-menopausal women and others with dementia.
36 onary heart disease (CHD) risk prediction in post-menopausal women compared with assessment using tra
37                     Participants were 84,537 post-menopausal women from the WHI (Women's Health Initi
38                                              Post-menopausal women have an increased risk of developi
39                                      Men and post-menopausal women have greater risk of developing co
40 noni), enhanced performances in athletes and post-menopausal women in clinical studies.
41  therapy (HRT) has been used increasingly by post-menopausal women in western countries.
42 se, risk factors for sudden cardiac death in post-menopausal women include African-American race, hig
43                                              Post-menopausal women more frequently have many traditio
44 ex/hormone status was grouped as: 1) men; 2) post-menopausal women not receiving hormone replacement
45 d risk of future systemic bone loss in these post-menopausal women not yet on anti-osteoporotic drugs
46              With the aging U.S. population, post-menopausal women now have the greatest population b
47  in two measures of olfactory function in 14 post-menopausal women receiving estrogen replacement the
48 en not receiving hormonal contraceptives; 4) post-menopausal women receiving hormone replacement ther
49 ng estrogen replacement therapy (ERT) and 48 post-menopausal women receiving no such therapy.
50 therapy to prevent cardiovascular disease in post-menopausal women remains contentious.
51  CV complications are more severe in men and post-menopausal women than in pre-menopausal women.
52  window hypothesis, i.e., that the brains of post-menopausal women ultimately lose their ability to r
53        In a preference trial, 18 symptomatic post-menopausal women underwent a passive heat stress to
54 ouble-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one
55 tase inhibitor administered after surgery to post-menopausal women with hormonally responsive breast
56            One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic os
57 d, double-blind, placebo-controlled trial of post-menopausal women with serum 25-hydroxyvitamin D con
58                        INTERPRETATION: Among post-menopausal women with severe osteoporosis, the risk
59 n a preference-controlled trial involving 21 post-menopausal women, 16 weeks of supervised moderate i
60 with increased incidence of breast cancer in post-menopausal women, and with increased mortality from
61 n reduces the risk of Alzheimer's disease in post-menopausal women, beta-amyloid (Abeta) burden in an
62 ascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of
63 n and -12.5 ml/yr (95% CI, -16.2 to -8.9) in post-menopausal women, compared with women menstruating
64 ssue, which are major sources of estrogen in post-menopausal women, could up-regulate hPRLR gene expr
65 was associated with decreasing HF risk among post-menopausal women, even in the absence of antecedent
66 declined more rapidly among transitional and post-menopausal women, in particular for FVC, beyond the
67           This cross-sectional study of 1256 post-menopausal women, recruited from the Buffalo center
68                                           In post-menopausal women, shorter total reproductive durati
69                            In hyperlipidemic post-menopausal women, statin therapy induced EAT regres
70                                           In post-menopausal women, the attenuation of PP amplificati
71 y benefits the outcome of cerebral stroke in post-menopausal women, we designed the present study to
72 cidence of HF hospitalization among healthy, post-menopausal women, whereas multivariable adjustment
73 erine (and tail) arteries from aged mice and post-menopausal women.
74 rdiovascular and bone remodelling markers in post-menopausal women.
75 e risk factors for breast cancer in pre- and post-menopausal women.
76 th increased bone resorption in osteoporotic post-menopausal women.
77 ne and cerebral ischemia incidents/impact in post-menopausal women.
78 onary artery calcium (CAC) in hyperlipidemic post-menopausal women.
79 SCD) and to identify risk factors for SCD in post-menopausal women.
80 is and telangiectasias were conducted on 410 post-menopausal women.
81 m bone-resorption biomarkers in subgroups of post-menopausal women.
82                  We included 26,160 healthy, post-menopausal women.
83 of ovarian hormone intervention in peri- and post-menopausal women.
84 ent heart failure (HF) hospitalization among post-menopausal women.
85 men and -5.2 ml/yr (95% CI, -8.3 to -2.0) in post-menopausal women.
86 was added to predictive models using TRFs in post-menopausal women.
87 centiles of a population-based study of 3100 post-menopausal women.
88 of alveolar crestal height and tooth loss in post-menopausal women.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。